The effects of medication on intraocular pressure in children with attention deficit hyperactivity disorder: A prospective study

Main Article Content

Oguz Guvenmez
Mehmet Cubuk
Serkan Gunes


attention deficit hyperactivity disorder, methylphenidate, atomoxetine, intraocular pressure, glaucoma


Attention deficit hyperactivity disorder (ADHD) is one of the most common psychiatric conditions in childhood. Psychopharmacological therapy is an effective treatment for ADHD. In this study, we primarily aim to investigate the effects of psychopharmacological agents on intraocular pressure (IOP) in children with ADHD. The sample included 82 children with ADHD and 36 healthy children aged between 8 and 12 years who were referred to the Department of Child and Adolescent Psychiatry in Hatay State Hospital, Hatay, Turkey. Children with ADHD were divided into two groups according to the medication used: methylphenidate (MPH) group and atomoxetine (ATX) group. Before treatment and after 1- and 6-month treatment period, IOP was measured by Goldmann applanation tonometry. There were no statistical differences in terms of age, gender, and IOP between the three groups (P > 0.05). After 1- and 6-month treatment, the IOP did not change significantly between baseline and 1 month or 6 months (P > 0.05). Children with ADHD may have an IOP similar to healthy children. Six-month treatment with MPH or ATX may not cause significant changes in IOP.

Abstract 2348 | PDF Downloads 680 HTML Downloads 129 XML Downloads 5


1. Izci F, Oguten EG. Methylphenidate induced intraocular pressure increase. Dusunen Adam. 2016;29:387. 6290413
2. Larrañaga-Fragoso P, Noval S, Rivero JC, et al. The effects of methylphenidate on refraction and anterior segment parameters in children with attention deficit hyperactivity disorder. J AAPOS. 2015;19:322–6. 2015.04.005
3. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adoles-cents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19:353–64. 1007/s00787-009-0054-3
4. Garnock-Jones KP, Keating GM. Atomoxetine: A review of its use in attention-deficit hyperactiv-ity disorder in children and adolescents. Paediatr Drugs. 2009;11:203–26. 00148581-200911030-00005
5. Alhatem FJ, Decker DH. Atomoxetine-induced mydriasis. J Child Adolesc Psychopharmacol. 2008;18:539–41. 0015
6. Bahali K, Ipek H, Yalcin O, et al. Atomoxetine-induced mydriasis in a child patient. Eur Child Adolesc Psychiatry. 2014;23:1231–2. https://doi. org/10.1007/s00787-013-0491-x
7. Lu CK, Kuang TM, Chou JCK. Methylphenidate (ritalin)-associated cataract and glaucoma. J Chinese Med Assoc. 2006;69:589–90. https://doi. org/10.1016/S1726-4901(09)70335-1
8. Soyer J, Jean-Louis J, Ospina LH, et al. Visual disorders with psychostimulants: A paediatric case report. Paediatr Child Health. 2019;24:153–5.
9. Ayyildiz D, Ayyildiz T. Ophthalmological find-ings in children and adolescents with attention deficit and hyperactivity disorder. Int Phys Med Rehab J. 2019;4:276–9.
10. Tripathi RC, Tripathi BJ, Haggerty C. Drug-induced glaucomas: Mechanism and manage-ment. Drug Saf. 2003;26:749–67. 10.2165/00002018-200326110-00002
11. Boonyaleephan S. Drug-induced secondary glau-coma. J Med Assoc Thai. 2010;93:118–22.
12. Lachkar Y, Bouassida W. Drug-induced acute angle closure glaucoma. Curr Opin Ophthalmol. 2007;18:129–33. 0b013e32808738d5
13. Corman SL, Fedutes BA, Culley CM. Atomoxetine: The first nonstimulant for the man-agement of attention-deficit/hyperactivity disor-der. Am J Health Syst Pharm. 2004;61:2391–9.
14. Bartlik B, Harmon G, Kaplan P. Use of methyl-phenidate in a patient with glaucoma and atten-tion-deficit hyperactivity disorder: A clinical dilemma. Arch Gen Psychiatry. 1997;54:188–9. 100018
15. Lewis H, Lewis J. Safe and effective methylphe-nidate therapy in a pediatric patient with glaucoma. ADHD Atten Deficit Hyperact Disord. 2012;4:37–9.